Migraine Survey in Gulf Region

Last Update: Jan 14, 2025
Real-world Experience of Patients Newly Started on Erenumab in the Gulf Region: a Longitudinal Prospective Observational Study
ClinicalTrials.gov Identifier:
NCT06237062
Novartis Reference Number:CAMG334AAE02
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The objective of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients newly started on erenumab over 12 weeks This is a longitudinal prospective descriptive primary data collection using a 20 min online survey. Patients will be selected by investigators (general neurologists, headache/migraine specialists) in primary care clinics and hospitals. After fulfilling the inclusion criteria, the patient will be asked to sign an online informed consent. A 5 min screener will follow after which the patient will be directed through a link to the full survey. The duration of data collection will be for 6 months since the start of survey rolling in each site across centers in the Gulf Region.

Condition
Migraine
Overall Status
Recruiting
Number of Participants
200
Start Date
Jun 05, 2024
Completion Date
Mar 30, 2025
Gender
All
Age(s)
18 Years - 100 Years (Adult, Older Adult)

Interventions

Other

erenumab

This is an observational study, there is no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients will be directed through a link to the full survey.

Eligibility Criteria

Inclusion Criteria:

* EM\& CM (with or without Medication Overuse Headache (MOH)) patients
* Newly Started on erenumab either 70 mg or 140 mg (first dose received within 1 month prior study enrollment and baseline endpoints collection)
* Ability to receive 3 monthly doses of erenumab.
* Age more than 18 years
* Males and Females
* Allowing the patients to be stable on 1 adjunctive migraine preventive medication (if present)
* Agreed to be included in the study and signed informed consent

Exclusion Criteria:

* Less than 18 years
* Age at onset of Migraine more than 50 years
* Any contraindications to the start of erenumab as per label
* Refusal to sign informed consent
* Inability to participate or restricted access to the online survey
* Enrolled in an interventional migraine-related study at the time of the study enrollement

United Arab Emirates

Novartis Investigative Site

Recruiting

Abu Dhabi,112412,United Arab Emirates

Novartis Investigative Site

Recruiting

Ras Al Khaimah,United Arab Emirates

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: +41613241111
Email: novartis.email@novartis.com

Source URL: *https://prod1.novartis.com/clinicaltrials/study/nct06237062*

List of links present in page

1. https://clinicaltrials.gov/ct2/show/NCT06237062
2. #trial-eligibility
3. tel:+41613241111
4. mailto:novartis.email@novartis.com